PressMarch 27, 2026 Otsuka to acquire methylone developer Transcend Therapeutics for up to $1.225 billion
PressMarch 16, 2026 SciSparc unit NeuroThera and Clearmind file Hong Kong patent for combination depression therapy
PressMarch 13, 2026 Numinus refocuses on clinical-trial-site network and practitioner training in corporate update
PressMarch 10, 2026 Clearmind publishes international patent covering weight-loss and fatty-liver therapy
PressMarch 10, 2026 AtaiBeckley says BPL-003 Phase 3 on track for Q2 2026 after successful FDA End-of-Phase 2 meeting
PressMarch 9, 2026 Gallego and McCormick introduce bill to create VA psychedelic 'centers of excellence'
PressMarch 3, 2026 PharmAla signs MDMA supply-and-data deal with Nautilus Sanctuary for U.S. first-responder PTSD trial
PressFebruary 26, 2026 Definium reports full-year 2025 results with $411.6M cash and three 2026 Phase 3 readouts on track
PressFebruary 26, 2026 AtaiBeckley reports positive Phase 2a topline for EMP-01 (oral R-MDMA) in social anxiety disorder
PressFebruary 23, 2026 PharmAla to supply Amsterdam UMC with LaNeo MDMA and develop single-capsule stability data
PressFebruary 23, 2026 FDA grants Breakthrough Therapy Designation to Reunion's luvesilocin (RE104) for postpartum depression
